Kwangdong Pharmaceutical Signs Co-Marketing and Distribution Agreement with MSD Korea for Adult-Only 21-Valent Pneumococcal Vaccine "CAPVAXIVE"

Kwangdong Pharmaceutical announced on the 4th that it has signed a domestic co-promotion (joint marketing and sales) agreement with MSD Korea for the adult-only 21-valent pneumococcal conjugate vaccine “CAPVAXIVE TM.”

Under this agreement, the two companies will jointly conduct domestic marketing and distribution from the time of CAPVAXIVE’s launch in the first quarter of 2026. Having already built a solid collaborative relationship through the co-promotion of the Human Papilloma Virus (HPV) vaccines “GARDASIL” and “GARDASIL 9,” the two companies will further expand their strategic partnership in the vaccine market through this new agreement.

CAPVAXIVE is a newly designed pneumococcal vaccine for the prevention of Invasive Pneumococcal Disease (IPD) and pneumococcal pneumonia in adults, characterized by its reflection of unmet needs based on the latest epidemiological profile of adult pneumococcal disease. In particular, by including eight unique serotypes (15A, 15C (deOAc15B), 16F, 23A, 23B, 24F, 31, 35B), it offers the broadest serotype coverage among pneumococcal conjugate vaccines currently approved in Korea as of February 4, 2026.

According to the approval information from the Ministry of Food and Drug Safety, CAPVAXIVE can be used for the prevention of invasive disease and pneumococcal pneumonia caused by pneumococcal serotypes in adults aged 18 years and older.

Choi Sungwon, CEO of Kwangdong Pharmaceutical, said, “This collaboration has enabled us to further strengthen our vaccine portfolio and establish a foundation to respond to broader preventive needs. Based on Kwangdong Pharmaceutical’s differentiated sales infrastructure and expertise, we will drive the successful market establishment of CAPVAXIVE and further enhance our competitiveness in the domestic vaccine market.”

Albert Kim, CEO of MSD Korea, said, “Building on more than 25 years of experience in stably supplying adult pneumococcal vaccines in Korea, MSD Korea will, through this partnership, lead adult-tailored strategies for the prevention of pneumococcal diseases and work together so that more adults can benefit from the preventive effects of CAPVAXIVE.”

This content was produced with the assistance of AI translation services.